Scholarlink

Background <p>Chromoblastomycosis (CBM) is a chronic and difficult-to-treat infection caused by dematiaceous fungi, primarily affecting the skin and subcutaneous tissues. In Southern China, <i>Fonsecaea monophora</i> is recognized as a predominant pathogen agent of CBM cases. Effective therapeutic strategies remain limited for this mycosis. However, berberine, a bioactive compound extracted from various traditional medicinal herbs, has attracted considerable attention due to its potent antimicrobial properties.</p> Methods <p>The study evaluated the antifungal efficacy of berberine against <i>F. monophora</i> through a series of in vitro studies, including antifungal susceptibility testing and time-kill curve analysis. Moreover, a <i>Galleria mellonella</i> infection model of <i>F. monophora</i> was also established for the comparative analysis of berberine’s efficacy.</p> Results <p>Berberine exhibited inhibitory activity against all tested strains. The minimum inhibitory concentrations (MICs) of berberine against <i>F. monophora</i> strains ranged from 16 to 64&#xa0;µg/mL, with a geometric mean of 49.74&#xa0;µg/mL. In the <i>Galleria mellonella</i> model, berberine treatment significantly prolonged the survival time of infected larvae.</p> Conclusion <p>These findings suggest that berberine has the potential, as a complementary treatment, for CBM. However, the current research is limited to in-vivo and preliminary in-vitro model involving a small number of fungal strains. Therefore, further validations through additional studies, such as involving murine model and other advanced experimental systems, will be necessary. </p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Inhibitory effects of berberine on Fonsecaea monophora in vitro and in vivo

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月17日

查看全文
  • Liya He,
  • Yong Zhu,
  • Xin Mei,
  • Bing Yu,
  • Sha Lu,
  • Dongdong Mo,
  • Ruiqiang Fan,
  • Xinsheng Chen,
  • Liyan Xi,
  • Ting Xie

摘要

Background

Chromoblastomycosis (CBM) is a chronic and difficult-to-treat infection caused by dematiaceous fungi, primarily affecting the skin and subcutaneous tissues. In Southern China, Fonsecaea monophora is recognized as a predominant pathogen agent of CBM cases. Effective therapeutic strategies remain limited for this mycosis. However, berberine, a bioactive compound extracted from various traditional medicinal herbs, has attracted considerable attention due to its potent antimicrobial properties.

Methods

The study evaluated the antifungal efficacy of berberine against F. monophora through a series of in vitro studies, including antifungal susceptibility testing and time-kill curve analysis. Moreover, a Galleria mellonella infection model of F. monophora was also established for the comparative analysis of berberine’s efficacy.

Results

Berberine exhibited inhibitory activity against all tested strains. The minimum inhibitory concentrations (MICs) of berberine against F. monophora strains ranged from 16 to 64 µg/mL, with a geometric mean of 49.74 µg/mL. In the Galleria mellonella model, berberine treatment significantly prolonged the survival time of infected larvae.

Conclusion

These findings suggest that berberine has the potential, as a complementary treatment, for CBM. However, the current research is limited to in-vivo and preliminary in-vitro model involving a small number of fungal strains. Therefore, further validations through additional studies, such as involving murine model and other advanced experimental systems, will be necessary.